(NASDAQ: DFTX) Definium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.33%.
Definium Therapeutics's earnings in 2026 is -$237,543,000.On average, 18 Wall Street analysts forecast DFTX's earnings for 2026 to be -$248,225,091, with the lowest DFTX earnings forecast at -$285,384,144, and the highest DFTX earnings forecast at -$211,862,226. On average, 17 Wall Street analysts forecast DFTX's earnings for 2027 to be -$194,378,821, with the lowest DFTX earnings forecast at -$280,258,006, and the highest DFTX earnings forecast at -$61,840,866.
In 2028, DFTX is forecast to generate -$76,270,401 in earnings, with the lowest earnings forecast at -$235,147,984 and the highest earnings forecast at $490,146,123.